Patents Assigned to Good Samaritan Hospital
-
Publication number: 20220296671Abstract: The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.Type: ApplicationFiled: February 25, 2022Publication date: September 22, 2022Applicants: Stealth BioTherapeutics Inc., Heart Institute Good Samaritan HospitalInventors: D. Travis Wilson, Robert A. Kloner
-
Patent number: 9345738Abstract: The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: GrantFiled: July 8, 2011Date of Patent: May 24, 2016Assignees: Stealth BioTherapeutics Corp., Heart Institute Good Samaritan HospitalInventors: D. Travis Wilson, Kenneth Borow, Robert A. Kloner, Sharon Hale
-
Patent number: 9314622Abstract: A method and system which provides wireless, noninvasive electrical stimulation to different muscle groups to allow the user to conduct physical activities, such as walking, by stimulating various muscle groups in the body at the correct times of activation or by stimulating muscle groups in a simulation mode when standing, sitting or lying down, whereby walking is not required to stimulate the various muscle groups. The system provides a small portable wearable system which utilizes available software, including Bluetooth technology, to provide electrical nerve stimulating pulses with low current, minimal phase charge which is controlled remotely and induce desired muscle contraction with increased comfort for the user. The present method and system applies electrical stimulation with accurate timing, based on a three-dimensional motion sensor, as a trigger to initiate stimulation and which is adapted to turn itself on and off when not walking.Type: GrantFiled: October 25, 2012Date of Patent: April 19, 2016Assignee: GOOD SAMARITAN HOSPITALInventors: David G. Embrey, Jeffrey Stonestreet, Gadi Alon
-
Publication number: 20140128939Abstract: A method and system which provides wireless, noninvasive electrical stimulation to different muscle groups to allow the user to conduct physical activities, such as walking, by stimulating various muscle groups in the body at the correct times of activation or by stimulating muscle groups in a simulation mode when standing, sitting or lying down, whereby walking is not required to stimulate the various muscle groups. The system provides a small portable wearable system which utilizes available software, including Bluetooth technology, to provide electrical nerve stimulating pulses with low current, minimal phase charge which is controlled remotely and induce desired muscle contraction with increased comfort for the user. The present method and system applies electrical stimulation with accurate timing, based on a three-dimensional motion sensor, as a trigger to initiate stimulation and which is adapted to turn itself on and off when not walking.Type: ApplicationFiled: October 25, 2012Publication date: May 8, 2014Applicant: Good Samaritan HospitalInventors: David G. Embrey, Jeffrey Stonestreet, Gadi Alon
-
Patent number: 7433727Abstract: The invention consists of a sensor with multiple indicating (sensing) electrodes covered with a selectively permeable membrane for monitoring fluid concentrations in a biological environment. The indicating electrodes respond to changes in certain analytes, such as glucose, through an enzyme-mediated reaction. The currents generated from the enzyme-mediated reactions are transmitted through radio signals to an external receiver where the information is processed and recorded. Through the use of various biomaterials and biochemicals associated with the sensor, the monitoring accuracy is improved and the overall viability is prolonged. The process of foreign body fibrosis (formation of a scar capsule around the implanted sensor) eventually limits the functional life of the device. We teach methods of delivery of certain biochemicals that can increase the functional life of the sensor by inhibiting the formation of the foreign body capsule or by stimulating the growth of capillaries into the capsule.Type: GrantFiled: September 24, 2004Date of Patent: October 7, 2008Assignee: Legacy Good Samaritan Hospital and Medical CenterInventors: W. Kenneth Ward, Michael D. Wood
-
Patent number: 6466810Abstract: The invention provides an electrochemical sensor system for measuring analyte concentrations in a fluid sample. The invention is particularly useful for measuring analytes such as glucose in a patient. An implantable glucose sensor includes a disc-shaped sensor body containing multiple anodes on opposing sides of the sensor body. Electrodes including an anode and a cathode are connected to a transmitter which transmits radio signals to an external receiver and computer where data is processed to yield glucose concentration figures. An enzyme layer coating the anodes specifically reacts with glucose to increase signals generated by the anodes in response to the presence of glucose. In an alternate embodiment, some of the anodes are coated with the enzyme to generate a first signal, and other anodes that are not coated generate a second signal for comparison with the first signal to eliminate effects of interfering substances on the accuracy of the glucose measurement.Type: GrantFiled: November 28, 2000Date of Patent: October 15, 2002Assignee: Legacy Good Samaritan Hospital and Medical CenterInventors: W. Kenneth Ward, Eric S. Wilgus
-
Patent number: 6212416Abstract: The invention provides an electrochemical sensor system for measuring analyte concentrations in a fluid sample. The invention is particularly useful for measuring analytes such as glucose in a patient. An implantable glucose sensor includes a disc-shaped sensor body containing multiple anodes on opposing sides of the sensor body. Electrodes including an anode and a cathode are connected to a transmitter which transmits radio signals to an external receiver and computer where data is processed to yield glucose concentration figures. An enzyme layer coating the anodes specifically reacts with glucose to increase signals generated by the anodes in response to the presence of glucose. In an alternate embodiment, some of the anodes are coated with the enzyme to generate a first signal, and other anodes that are not coated generate a second signal for comparison with the first signal to eliminate effects of interfering substances on the accuracy of the glucose measurement.Type: GrantFiled: May 22, 1998Date of Patent: April 3, 2001Assignee: Good Samaritan Hospital and Medical CenterInventors: W. Kenneth Ward, Eric S. Wilgus
-
Patent number: 5935856Abstract: A method of inhibiting the growth of bFGF-dependent neoplastic cells is disclosed. The method includes the steps of accessing a selected colony of such cells and adding a bFGF-specific antisense primer to such colony. By performing the adding step, there is downregulating of the expression of colony-intracellular bound bFGF, and by performing the downregulating step, there is inhibiting of bFGF-promoted growth of cells in the colony.Type: GrantFiled: December 9, 1996Date of Patent: August 10, 1999Assignee: Legacy Good Samaritan Hospital And Medical CenterInventor: Richard S. Morrison
-
Patent number: 5753522Abstract: A composition useful in a method for diagnosing cancer-associated retinopathy including the steps of acquiring a purified aliquot of 26 kDa protein, and, utilizing the protein, or a unique fragment thereof, to perform a patient-serum assay to identify in a sample of a patient's serum the presence of autoantibodies to the 26 kDa protein autoantigen.Type: GrantFiled: April 10, 1995Date of Patent: May 19, 1998Assignee: Legacy Good Samaritan Hospital and Medical CenterInventors: Arthur S. Polans, Krzysztof Palczewski
-
Patent number: 5583116Abstract: A method of inhibiting the growth of bFGF-dependent neoplastic cells is disclosed. The method includes the steps of accessing a selected colony of such cells and adding a bFGF-specific antisense primer to such colony. By performing the adding step, there is downregulating of the expression of colony-intracellular bound bFGF, and by performing the downregulating step, there is inhibiting of bFGF-promoted growth of cells in the colony.Type: GrantFiled: December 21, 1994Date of Patent: December 10, 1996Assignee: Good Samaritan Hospital and Medical CenterInventor: Richard S. Morrison